233 related articles for article (PubMed ID: 25365139)
21. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
22. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
[TBL] [Abstract][Full Text] [Related]
23. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
24. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
26. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
[TBL] [Abstract][Full Text] [Related]
27. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
Front Immunol; 2021; 12():698312. PubMed ID: 34489945
[TBL] [Abstract][Full Text] [Related]
28. Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis.
Villar-Vázquez R; Padilla G; Fernández-Aceñero MJ; Suárez A; Fuente E; Pastor C; Calero M; Barderas R; Casal JI
Proteomics; 2016 Apr; 16(8):1280-90. PubMed ID: 26915739
[TBL] [Abstract][Full Text] [Related]
29. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Anderson KS; Ramachandran N; Wong J; Raphael JV; Hainsworth E; Demirkan G; Cramer D; Aronzon D; Hodi FS; Harris L; Logvinenko T; LaBaer J
J Proteome Res; 2008 Apr; 7(4):1490-9. PubMed ID: 18311903
[TBL] [Abstract][Full Text] [Related]
30. Significant association of serum autoantibodies to TYMS, HAPLN1 and IGFBP5 with early stage canine malignant mammary tumours.
Chang SC; Yuan SH; Li CY; Chang HM; Wang HC; Pan YA; Hsueh PC; Wu CC; Yang Y; Liu HP
Vet Comp Oncol; 2021 Mar; 19(1):172-182. PubMed ID: 33038064
[TBL] [Abstract][Full Text] [Related]
31. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
[TBL] [Abstract][Full Text] [Related]
32. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody signature in hepatocellular carcinoma using seromics.
Zhang S; Liu Y; Chen J; Shu H; Shen S; Li Y; Lu X; Cao X; Dong L; Shi J; Cao Y; Wang X; Zhou J; Liu Y; Chen L; Fan J; Ding G; Gao Q
J Hematol Oncol; 2020 Jul; 13(1):85. PubMed ID: 32616055
[TBL] [Abstract][Full Text] [Related]
35. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer.
Duan Y; Cui C; Qiu C; Sun G; Wang X; Wang P; Ye H; Dai L; Shi J
Dis Markers; 2022; 2022():6657820. PubMed ID: 35273656
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.
Yang Q; Qin J; Sun G; Qiu C; Jiang D; Ye H; Wang X; Dai L; Zhu J; Wang P; Zhang J
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00284. PubMed ID: 33346593
[TBL] [Abstract][Full Text] [Related]
37. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer.
Qiu C; Wang B; Wang P; Wang X; Ma Y; Dai L; Shi J; Wang K; Sun G; Ye H; Zhang J
Cancer Sci; 2021 Aug; 112(8):3388-3400. PubMed ID: 34115421
[TBL] [Abstract][Full Text] [Related]
39. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
40. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]